Clinical Trial: An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07084584) titled 'An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia' on July 17.

Brief Summary: Study GB3226-DEV-001 is a Phase 1/2, open-label, dose-escalation and expansion study of GB3226 in the treatment of relapsed or refractory acute myeloid leukaemia

Study Start Date: June 10, 2026

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory Acute Myeloid Leukemia (AML)

Intervention: DRUG: GB3226

GB3226: Dual inhibitor of ENL-YEATS and FLT3 pathways Administration: Oral, daily dosing in 28-day cycles

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Galecto Biotech...